This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mentor Offers $2.2 Billion for Medicis

A fourth player has walked onstage in the cosmetic surgery takeover saga.

Sunday night, Mentor (MNT) offered to acquire Medicis (MRX) for $34.81 a share in stock, or about $2.2 billion.

Medicis, which itself is involved in a bidding war for Inamed (IMDC), said its board unanimously rejected the Mentor proposal.

"The proposal by Mentor is inappropriate in light of the recent trading history of the two companies and the pending stockholder votes on the Inamed merger," Medicis said. Mentor's stock has risen 79% this year, while Medicis' has fallen 19%.

"We continue to unanimously recommend that our stockholders vote in favor of our proposed merger with Inamed as we believe that a combination with Inamed will maximize stockholder value," Medicis said.

Separately, Allergan (AGN), Medicis' rival for Inamed, began its exchange offer for the company. Botox-maker Allergan has offered $84 a share, or $3.2 billion, for Inamed, which specializes in skin-care products, breast implants and obesity products.

Allergan's offer is $84 in cash or 0.8498 shares of Allergan for each share of Inamed. The target company's board previously said it would review the unsolicited offer from Allergan, of Irvine, Calif., whose other main business is eye-care medications.

Medicis, of Scottsdale, Ariz., specializes in skin-care products ranging from acne drugs to an antiwrinkle treatment. It made a cash and stock bid for Inamed in March, which was then worth $2.8 billion, or $75 a share. The deal included $30 in cash and 1.4205 Medicis shares for each share of Inamed, of Santa Barbara, Calif. Because Medicis' stock has fallen, the offer is now worth about $69 a share.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MRX $0.00 0.00%
AGN $240.22 1.21%
IMDC $0.03 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs